Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.
5 COVID skin rashes: Dermatologists share tips to identify and treat viral skin conditions
We tend to think of COVID-19 as a respiratory illness. But, like many viruses, COVID can also affect your skin and cause ...